“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

August 29, 2026
Vijay Pande — who left a16z’s roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a “discovery” science to an “engineering” one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.

The Theragun Sense makes everyday recovery surprisingly easy

August 29, 2026
As my 20s are set to come to an end later this year, I’ve officially reached the age where sleeping in the wrong position or stretching just a little too far can cause aches and pains. I’ve always been somewhat skeptical of massage guns, mostly because I’ve tried a few off-brand ones and just assumed […]